Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.04 is 154% below its 5-year average of -0.41, near the low end of its 5-year range (-1.04–-0.13).
112.24% below its 12-month average of -0.49.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.50.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 26 comparable quarters.
EARNINGS PER SHARE (EPS)
-1.04
EARNINGS PER SHARE (EPS) AVG TTM
-0.49
EARNINGS PER SHARE (EPS) AVG 3Y
-0.48
EARNINGS PER SHARE (EPS) AVG 5Y
-0.41
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-112.24%
CURRENT VS 3Y AVG
-115.54%
CURRENT VS 5Y AVG
-153.66%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Alpha Tau Medical Ltd
Market Cap
$1.33B
Earnings Per Share (EPS)
-1.04
TTM Avg
-0.49
3Y Avg
-0.48
5Y Avg
-0.41
Market Cap
$1.33B
Earnings Per Share (EPS)
-3.68
TTM Avg
-3.44
3Y Avg
-2.54
5Y Avg
-10.12
Market Cap
$1.35B
Earnings Per Share (EPS)
N/A
TTM Avg
-2.33
3Y Avg
-2.33
5Y Avg
-2.33
Market Cap
$1.37B
Earnings Per Share (EPS)
N/A
TTM Avg
-1.26
3Y Avg
-1.26
5Y Avg
-1.26
Market Cap
$1.40B
Earnings Per Share (EPS)
-8.88
TTM Avg
53.77
3Y Avg
24.70
5Y Avg
19.33
Market Cap
$1.23B
Earnings Per Share (EPS)
N/A
TTM Avg
-3.20
3Y Avg
-3.20
5Y Avg
-3.20
Market Cap
$1.44B
Earnings Per Share (EPS)
5.37
TTM Avg
-2.79
3Y Avg
-4.06
5Y Avg
-3.18
Market Cap
$1.22B
Earnings Per Share (EPS)
0.18
TTM Avg
0.04
3Y Avg
-0.14
5Y Avg
-0.31
Market Cap
$1.22B
Earnings Per Share (EPS)
-0.14
TTM Avg
0.06
3Y Avg
-0.09
5Y Avg
-0.17
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alpha Tau Medical Ltd (DRTS) | $1.33B | -1.04 | -0.49 | -0.48 | -0.41 |
| ArriVent BioPharma, Inc. (AVBP)vs › | $1.33B | -3.68 | -3.44 | -2.54 | -10.12 |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.35B | N/A | -2.33 | -2.33 | -2.33 |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.37B | N/A | -1.26 | -1.26 | -1.26 |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.40B | -8.88 | 53.77 | 24.70 | 19.33 |
| Kardigan, Inc. (KARD)vs › | $1.23B | N/A | -3.20 | -3.20 | -3.20 |
| AnaptysBio, Inc. (ANAB)vs › | $1.44B | 5.37 | -2.79 | -4.06 | -3.18 |
| Cronos Group Inc. (CRON)vs › | $1.22B | 0.18 | 0.04 | -0.14 | -0.31 |
| MannKind Corporation (MNKD)vs › | $1.22B | -0.14 | 0.06 | -0.09 | -0.17 |
| Innovage Holding Corp. (INNV)vs › | $1.23B | -0.02 | -0.12 | -0.17 | -0.18 |
Trailing EPS (TTM)
$-1.04
Forward EPS (Est.)
$-0.96
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.53 |
| 2024-12-31 | -0.45 |
| 2023-12-31 | -0.42 |
| 2022-12-31 | -0.53 |
| 2021-12-31 | -0.40 |
| 2020-12-31 | -0.13 |
| 2019-12-31 | -0.13 |
